Version 1
: Received: 24 September 2024 / Approved: 24 September 2024 / Online: 25 September 2024 (10:25:00 CEST)
How to cite:
Adwan, S.; Al-Akayleh, F.; Qasmieh, M.; Obeidi, T. Enhanced Ocular Drug Delivery of Dexamethasone Using Chitosan-Coated Soluplus® Based Mixed Micellar System. Preprints2024, 2024091939. https://doi.org/10.20944/preprints202409.1939.v1
Adwan, S.; Al-Akayleh, F.; Qasmieh, M.; Obeidi, T. Enhanced Ocular Drug Delivery of Dexamethasone Using Chitosan-Coated Soluplus® Based Mixed Micellar System. Preprints 2024, 2024091939. https://doi.org/10.20944/preprints202409.1939.v1
Adwan, S.; Al-Akayleh, F.; Qasmieh, M.; Obeidi, T. Enhanced Ocular Drug Delivery of Dexamethasone Using Chitosan-Coated Soluplus® Based Mixed Micellar System. Preprints2024, 2024091939. https://doi.org/10.20944/preprints202409.1939.v1
APA Style
Adwan, S., Al-Akayleh, F., Qasmieh, M., & Obeidi, T. (2024). Enhanced Ocular Drug Delivery of Dexamethasone Using Chitosan-Coated Soluplus® Based Mixed Micellar System. Preprints. https://doi.org/10.20944/preprints202409.1939.v1
Chicago/Turabian Style
Adwan, S., Madeha Qasmieh and Teiba Obeidi. 2024 "Enhanced Ocular Drug Delivery of Dexamethasone Using Chitosan-Coated Soluplus® Based Mixed Micellar System" Preprints. https://doi.org/10.20944/preprints202409.1939.v1
Abstract
Background: This study introduces a novel dexamethasone (DEX) mixed micellar system (DEX-MM) using Soluplus® and Pluronic F-127 (PF127) to enhance ocular drug delivery. The enhancement of ocular application properties was achieved by creating a chitosan-coated DEX-MM (DEX-CMM), which promotes better adherence to the ocular surface, thereby improving drug absorption; Methods: Using the solvent evaporation method, a formulation was developed with a Soluplus® to drug ratio of 1:10, enhanced with 0.25% PF127. After dispersing in water, 1% chitosan (CS) was added. The stability and integrity of DEX within the micelles were verified using attenuated total reflection-fourier transform infrared spectroscopy (ATR-FTIR) and differential scanning calorimetry (DSC). Additionally, in vitro and ex vivo drug release studies were con-ducted; Results: DEX-CMM (F6) demonstrated a particle size of 151.9±1 nm and a polydispersity index (PDI) of 0.168±0.003, suggesting uniformity and high electrostatic stability with a zeta po-tential of +35.96±2.13 mV. The non-Fickian drug release mechanism indicated prolonged drug retention. Comparative analyses showed DEX-CMM outperforming a standard DEX suspension in drug release and ocular tissue permeation, with flux measurements significantly higher than the DEX suspension; Conclusion: The study confirmed the efficacy of DEX-CMM in enhancing drug delivery to ocular tissues, evidenced by improved permeability. Safety evaluations using the HET-CAM test demonstrated that DEX-CMM was non-irritant, supporting its potential for effective ocular drug delivery.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
